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Abstract
Prostate cancer is a common malignancy among men in Western countries. Recently the morbidity
and mortality of prostate cancer increase dramatically in several oriental countries including
China. Rapidly evolving technology in molecular biology such as high-throughput sequencing and
integrative analysis of genomic and transcriptomic landscapes have enabled the identification of
key oncogenic events for prostate cancer initiation, progression and resistance to hormonal
therapy. These surging data of prostate cancer genome also provide insights on ethnic variation
and the differences in histological subtype of this disease. In this review, differences in the
incidence of prostate cancer and the prevalence of main genetic alterations between Asian and
Western populations are discussed. We also review the recent findings on the mechanisms
underlying neuroendocrine differentiation of prostate cancer and the development of small cell
neuroendocrine carcinoma after androgen deprivation therapy.
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Prostate cancer is the second most commonly diagnosed nondermatologic cancer and the
sixth leading cause of cancer-related deaths in men worldwide [1]. The morbidity and
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mortality of this hormone-related cancer vary significantly among different countries and
racial/ethnic populations. In western countries, prostate cancer is the most prevalent
malignancy for men [1]. In 2013, approximately 238590 new cases of prostate cancer are
expected in the United States, which account for 28% of all newly diagnosed cancers in
American men, and it is estimated that about 29720 American men will die from this disease
this year [2]. In several developing countries located primarily in the Caribbean, South
America and sub-Saharan Africa, prostate cancer surpasses lung cancer and
gastroenterological cancer and is the leading cause of cancer deaths in men [3].
1 The difference in the incidence of prostate cancer among different ethnic
groups
In contrast, the incidence and mortality rates of prostate cancer are much lower in Asian
countries including China, India, Japan, Philippines, South Korea, Thailand and Vietnam
[3,4], although it has increased significantly in most of these countries in recent years, with
about 12%–14% average annual increase in China and South Korea [3]. The significant
differences in the incidence of prostate cancer between Asian countries and Western
countries may be attributed to dietary and lifestyle-related factors, as well as differences in
the use of prostate specific antigen (PSA) screening and access to medical care [4].
However, the epidemiological studies of Asian immigrants living in North America or
European continents reported that the incidence and mortality rates of prostate cancer among
these Asian immigrants are 50%–80% lower than those for non-Hispanic whites and Africa
Americans [2,4], suggesting that in addition to environmental influences, genetic
heterogeneity also contributes to prostate carcinogenesis.
To identify genetic variants associated with prostate cancer risk, multiple genome-wide
association studies (GWAS) have been carried out in populations of European descent,
African-Americans, Japanese and Chinese. So far 77 single nucleotide polymorphisms
(SNPs) associated with prostate cancer susceptibility have been identified [5,6], including
two new risk loci, 9q31.2 and 19q13.4, which were found to be significantly associated with
predisposition to prostate cancer in a Han Chinese population [7], and 23 new susceptibility
loci that were recently identified using the iCOGS custom genotyping array in a linkage
study with a larger pool of samples of European ancestry [5]. Unlike the previously
identified loci that were associated exclusively with non-aggressive prostate cancer, 16 out
of these 23 new susceptibility loci were found to be associated with aggressive as well as
non-aggressive disease, although none of the new loci are associated exclusively with the
indolent form of prostate cancer [5].
Of the 23 newly identified susceptibility loci for prostate cancer, rs11650494 is located at
chromosome 17q21, a gene-dense locus that contains several prostate cancer candidate
genes such as HOXB13 and SPOP [5]. Interestingly, by exome sequencing 202 genes on
chromosome 17q21–22, a rare but recurrent germline mutation in the HOXB13 gene
(HOXB13 G84E) was reported to be highly associated with familial prostate cancer in
Caucasians [8]. Although the same mutation was not detected in Chinese men, a novel rare
mutation (G135E) in HOXB13 was found to be associated with increased prostate cancer
risk among Chinese men [9]. HOXB13 is a member of the homeodomain family of
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transcription factors, which has been implicated in normal prostate development [10] as well
as cancer pathogenesis in tumors of several epithelial tissue origins [11–13]. However, the
definitive role of HOXB13 mutations in prostate carcinogenesis remains unclear. Similarly,
Barbieri et al. [14] described that 6%–13% of localized primary prostate cancer samples
harbor mutations in SPOP, a gene encoding the substrate-binding subunit of a cullin-based
E3 ubiquitin ligase. While wild-type SPOP protein interacts directly with steroid receptor
coactivator SRC-3 and enhances its ubiquitin-dependent proteasomal degradation to control
the transcriptional activity of androgen receptor (AR), it has been recently demonstrated that
most prostate cancer-associated SPOP mutants lack the capacity to promote the turnover of
SRC-3 protein and thus display attenuated tumor suppressor effects in prostate cancer cell
lines [15]. Consistently, in vitro studies showed that forced expression of SPOP mutant or
siRNA-mediated knockdown of SPOP led to increased invasion, but no significant changes
in cell growth and viability [14], suggesting that SPOP protein could function as a tumor
suppressor in the prostate.
2 Differences in the prevalence of prostate oncogenic events among
different ethnic groups
In the past decade, rapidly evolving technologies have revolutionized our understanding of
the cellular and molecular basis for the development of prostate cancer. In addition to the
aforementioned SNPs associated with prostate cancer susceptibility, a variety of genetic and
epigenetic alterations have been found to be involved in prostate cancer initiation,
progression, metastasis and drug resistance. Recurrent gene fusions involving several
members of ETS transcription factor family (ERG, ETV1, ETV4 or ETV5) were found to be
the most frequent genetic alterations in prostate cancer, which can be detected in as many as
50%–70% of prostate cancer samples [16,17]. ETS gene fusions resulting from either
interstitial deletion or chromosomal translocation lead to the generation of a handful of
fusion transcripts that commonly contain 5′ regulatory elements from androgen-responsive
genes, such as TMPRSS2, and the coding sequence of ETS transcription factors. The
TMPRSS2-ERG fusion at chromosome 21q22 is the predominant subtype of ETS fusions
[17,18]. The prevalence of the TMPRSS2-ERG fusion in prostate cancer appears to vary in
different ethnic groups, with the highest frequencies of occurrence in Caucasians (~50%)
[19,20], modest in African Americans (24%–31%) [19,20] and much lower frequencies in
Asian populations (8%–21%) [19,21–23], indicating that distinct genetic alterations may
drive prostate cancer development in different ethnic groups (Table 1).
Similar ethnic differences have also been demonstrated in PTEN status, another common
early event involved in prostate carcinogenesis. In Western countries, loss or alteration of at
least one PTEN allele is frequently present in primary prostate cancer, and is correlated with
disease progression to the metastatic stage [31,32]. It has been shown that approximately
40%–70% of primary prostate tumors have PTEN deletion, resulting in activation of the
PI3K-AKT pathway [30,31]. By parallel comparison of the frequencies of PTEN deletion/
inactivation among prostate cancer samples from China and the United Kingdom, Mao et al.
[24] revealed that only 34% of Chinese tissue specimens displayed low levels of PTEN,
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although the frequency of PTEN inactivation (69.8%) in specimens from the United
Kingdom were similar to that previously published for Western samples.
The low prevalence of ERG gene fusion and PTEN deficiency in Chinese patients with
prostate cancer suggests that alternative molecular mechanisms may play important roles in
the development of prostate cancer in Asian men. Using RNA-seq technology to profile the
changes in the transcriptome of primary prostate cancer samples from China, Ren et al. [21]
reported that two novel gene fusions, CTAGE5-KHDRBS3 and USP9Y-TTTY15, occurred at
high frequencies (~35%) in Chinese patients [21]. Two additional gene fusions, SDK1-
AMACR and RAD50-PDLIM4 were also found with relatively lower prevalence (24%–28%)
in this cohort of Chinese descent. Although the functional relevance and clinical significance
of these novel gene fusions remain elusive, the high recurrence of these gene rearrangements
indicates that unique genetic alterations in alternative pathways may affect prostate
oncogenesis among Asian patients.
In addition, the differences in activated RAS-RAF-MAPK signaling pathway also have been
characterized between Asian and Western patients with prostate cancer. Although
constitutive activation of RAS-RAF-MAPK pathway occurs in a majority of advanced
prostate tumors, the incidence of direct mutations of the upstream activators such as KRAS
and BRAF are not commonly found in prostate cancer [31]. However, it has been reported
that the frequency of KRAS mutations in prostate cancer patients from East Asian countries
was much higher than that in American cases. In contrast to a very low prevalence in
American patients (up to 3%) [25,31], about 7.3% of Korean patients [26], 9.1%–12.5% of
Chinese patients [27,28], and 10%–17% of Japanese patients [25,29] harbor KRAS
mutations. A similar difference in the frequency of BRAF mutation also has been reported in
prostate cancer samples from Caucasian populations and men of Korean descent [26,33].
Furthermore, it has been recently described that although rearrangements of BRAF and
RAF1 occur at a comparable frequency between Chinese and Western samples, the
prevalence of BRAF copy number gain in Chinese patients was significantly higher than that
in patients for the United Kingdom (29% vs. 9.2%) [28]. Taken together, these results
indicate that the RAS-RAF-MAPK signaling pathway may be more important for prostate
cancer pathogenesis in Asian men than in Western men.
3 Castration-resistant prostate cancer and neuroendocrine differentiation
Despite the considerable differences in epidemiology and etiology of prostate cancer
between Asian and Western countries, prostate cancer patients of different ethnic groups are
currently treated with the same modalities mainly based on tumor grade and stage. We know
very well now that a large portion of these patients have indolent tumors that will impact
neither quality of life nor life expectancy, so that active surveillance is a preferred option.
Localized cancers are treated with surgery or radiation with similar efficacy. For advanced
and metastatic prostate cancer, hormonal therapy that inhibits androgen production and/or
blocks androgen receptor (AR) function is the first-line treatment. However, many patients
experience only a short term disease regression, and nearly all of them will eventually recur
with castration-resistant prostate cancer (CRPC). During the past several decades, the
cellular and molecular basis underlying the development of CRPC has been intensively
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investigated. Diverse mechanisms have been proposed, including sustained intratumoral
synthesis of androgen, amplification of AR gene, gain-of-function mutations and alternative
splice variants of AR, changes in co-regulatory molecules, ligand-independent activation of
AR signaling as well as other AR-independent pathways that facilitate cancer cell survival
and growth under androgen-depleted conditions [34]. Recently, an integrated genetic study
of 50 heavily pre-treated CRPC samples obtained at rapid autopsy revealed the mutational
landscape of lethal metastatic CRPC. In addition to previously reported recurrent genomic
alterations such as PTEN, AR, RB1, TP53 and APC mutations, several novel somatic
mutations in multiple chromatin/ histone modifiers including MLL2, UTX and ASXL1 as
well as transcription factors FOXA1 and ETS2 were found in CRPC [35].
In addition to these identified molecular alterations, a pathological characteristic referred as
neuroendocrine differentiation of prostate cancer has also been demonstrated to be
significantly associated with the development of CRPC [36–38]. Epithelia of mouse and
human normal prostate consist of three types of differentiated cells: basal cells, luminal
secretory cells, and neuroendocrine cells, which are proposed to be derived from a common
pool of prostate stem/progenitor cells [39]. The luminal cells are columnar epithelial cells
constituting the bulk of the polarized glandular structures, with high levels of AR expression
and AR-dependent secretory machinery; whereas basal cells are localized between the
luminal cells and the underlying basement membrane, and express p63 and relatively low
levels of AR. Neuroendocrine cells constitute a minor population (~1%) of the total
epithelial cells in the normal prostate, and are scattered throughout the epithelial
compartment and can be detected by immunohistochemical (IHC) staining with
neuroendocrine cell-specific markers such as chromogranin A or synaptophysin [38]. Due to
the lack of nuclear AR expression in neuroendocrine cells [40,41], neuroendocrine cells in
normal prostate are resistant to castration, while androgen ablation leads to apoptosis of the
majority of luminal cells and growth arrest of basal cells [42].
In prostate adenocarcinoma, the predominant histological subtype of human prostate cancer,
the neoplastic glands are mainly composed of proliferating luminal type cancerous cells, and
complete loss of basal cells. However, scattered or nests of neuroendocrine cells are also
present in almost all cases of prostate adenocarcinoma [43], with varied ratios of
neuroendocrine to acinar-type cells in different patients. Increasing evidence supports the
notion that these neuroendocrine tumor cells are different from their counterparts in the
normal prostate gland, in terms of their cellular morphology and expression of lineage/
tumor-specific markers including cytokeratin 5/18 and AMACR [36,41], indicating that
neuroendocrine tumor cells are one type of bona fide epithelial constituent of prostate cancer
(Figure 1). Recent studies to assess ERG gene fusion status in neuroendocrine tumor cells by
FISH analysis consistently showed that despite the lack of ERG protein expression, the
TMPRSS2-ERG fusion can be detected in neuroendocrine cells that intermingle with ERG
rearrangement positive adenocarcinoma component within the same tumor foci [44]. These
findings further support the notion that unlike normal neuroendocrine cells, neuroendocrine
tumor cells could share a common cellular origin with luminal type cancer cells.
Interestingly, neuroendocrine tumor cells also display several unique features distinct from
luminal secretory-type cancer cells in prostate cancer. While highly proliferating luminal
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cancer cells are generally positive for AR and PSA, neuroendocrine cells in prostate
adenocarcinoma are usually quiescent and lack expression of AR and PSA [40,41]. Due to
these intrinsic features of neuroendocrine tumor cells, hormonal therapy of prostate
adenocarcinoma usually causes an increase in neuroendocrine differentiation and sometimes
induces the development of secondary small cell neuroendocrine carcinoma (SCNC) (Figure
1). Unlike adenocarcinoma, SCNC of the prostate does not show glandular structure but has
a solid sheet-like growth pattern. The tumor cells are small with scant cytoplasm, finely
granular and homogeneous chromatin and no prominent nucleoli. Nuclear molding, crush
artifact, mitotic and apoptotic figures are common histologic findings. SCNC is extremely
aggressive and is often widely metastatic at the time of diagnosis. It does not respond to
hormonal therapy and usually leads to death within a year [37,38,45].
It has been increasingly recognized that neuroendocrine differentiation following hormonal
therapy is associated with tumor progression and castration resistance [41,45,46]. However,
it remains controversial whether there is a causal relationship between the increased
neuroendocrine differentiation and CRPC development. Although the physiological roles of
neuroendocrine cells in prostate organogenesis and functional regulation are largely
unknown, it is proposed that neuroendocrine cells could interact with other types of prostate
epithelial cells and stromal cells via various mechanisms, due to their dual properties of
neurons and endocrine cells, such as dendrite-like cytoplasmic extensions and abundant
neurosecretory granules containing histamine, serotonin, neuron-specific enolase and many
other peptides/neuropeptides and cytokines [36]. In prostate cancer, especially under the
androgen-deprived environment, neuroendocrine tumor cells may promote the androgen-
independent growth of the luminal type prostate cancer cells [36]. Mechanistically, the
growth-promoting function of neuroendocrine tumor cells may be mediated by the paracrine
effects of peptide hormones such as bombesin/gastrin-releasing peptide family of
neuropeptides, which are secreted from neuroendocrine tumor cells and could stimulate
androgen-independent survival, growth and metastasis of the neighboring luminal type
prostate cancer cells [47] (Figure 1).
4 The cellular origins and key genetic events for SCNC
To date, the cellular origin of neuroendocrine tumor cells in prostate adenocarcinoma is
unclear. Given the pluripotency of prostate stem cells/progenitors that can give rise to basal,
luminal and neuroendocrine cells in the regeneration assay [48–50], it is proposed that
neuroendocrine tumor cells in prostate adenocarcinoma may be derived from prostate stem
cells that are transformed by a series of oncogenic events. On the other hand, several
preclinical studies showed that in an androgen-depleted setting or upon treatment with IL-6,
EGF or other agents that elevate the intracellular cyclic AMP, luminal type cancer cells
could undergo a process of transdifferentiation to acquire the morphology and lineage
specific markers of neuroendocrine cells [51–55], suggesting that neuroendocrine tumor
cells could be alternatively derived from luminal cancer cells in response to the pressure of
surviving in an androgen-depleted condition. This transdifferentiation model of
neuroendocrine tumor cells is further supported by a recent study of secondary SCNC,
showing that prostate luminal cell lines (RWPE-1 and LNCaP) have the ability to
transdifferentiate into cells with a neuroendocrine-like phenotype when they were stably
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transfected with transcription factor N-myc or Aurora kinase A (AURKA), a serine/
theronine kinase involved in cell cycle regulation [44].
Using next-generation RNA sequencing and oligonucleotide arrays, Beltran et al. [44]
showed that in contrast to the lower prevalence (5%) in localized prostate adenocarcinoma,
about 40% of metastatic SCNC displayed concurrent overexpression and amplification of
AURKA and N-myc gene (MYCN), indicating that N-myc and AURKA could play important
roles in the development of SCNC of the prostate. Moreover, the preclinical studies with an
AURKA inhibitor PHA-739358 demonstrated that this kinase antagonist has specific
inhibitory effects on the growth of neuroendocrine tumor cells in cell culture and xenograft
models [44], suggesting that enhanced AURKA kinase activity could be essential for the
maintenance of SCNC. However, the definitive mechanisms underlying AURKA/N-myc-
associated neuroendocrine differentiation remain unknown. The contributions of other
genetic alterations, such as decreased expression of transcription factor REST and
upregulation of epithelial-mesenchymal transition associated molecules [56], to
neuroendocrine differentiation and tumor growth should be determined in future studies.
In contrast to the absence of proliferative activity of neuroendocrine cells in benign prostate
tissues and prostate adenocarcinomas, neuroendocrine cells in primary (de novo) or
secondary SCNC are highly proliferative, which results in almost all patients dying within
one year following diagnosis [38,57,58]. The molecular mechanisms underlying the
difference in the cell cycle status of neuroendocrine cells in benign prostate/adenocarcinoma
and SCNC remain unclear. Our previous study demonstrated that interleukin-8 (IL-8), a
cytokine potentially involved in androgen-independent growth of prostate cancer [59], and
its receptor CXCR2 are exclusively expressed by neuroendocrine tumor cells in prostate
adenocarcinoma [60]. Given the recent findings showing activation of CXCR2 by IL-8 leads
to cellular senescence in a p53-dependent manner [61], we propose that the IL-8-CXCR2-
p53 axis could be the major regulatory signaling pathway to maintain the neuroendocrine
cells of benign prostate and adenocarcinoma in a quiescent state. In a recent study, we
showed that the expression of wild-type p53 protein is required for the growth-inhibitory
effects of IL-8-CXCR2 signaling on two different prostate cancer cell lines [62], which
provides experimental evidence to support our hypothesis. Importantly, while
neuroendocrine cells in benign prostate and adenocarcinoma express wild-type p53, IHC
analysis of SCNC samples revealed that the majority of the NE tumor cells in SCNC display
strong and diffuse nuclear p53 staining, suggesting that p53 is frequently mutated in SCNC
[62]. Furthermore, targeted sequencing of exons 5–10 of TP53 gene showed that five of
seven cases of SCNC harbor a recurrent p53 mutation (D184N) [62], supporting the notion
that p53 missense mutation in neuroendocrine cells could be the critical genetic event in the
development of prostate SCNC.
5 Animal models of SCNC
The identification of p53 protein as a key molecular determinant for the regulation of
neuroendocrine cell proliferation and quiescence not only offers the critical link between the
transformation of neuroendocrine cells and the development of prostate SCNC, but also
provides a mechanistic explanation for the neuroendocrine phenotype of prostate tumors
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from the transgenic adenocarcinoma of mouse prostate (TRAMP) model. The TRAMP
transgenic mouse strain is engineered to express the SV40 virus large T and small t tumor
antigens in prostate epithelial cells under the control of the AR-responsive rat probasin
promoter [63,64]. These mice ultimately develop predominantly SCNC and metastasis to
distant sites, with limited signs of the formation of prostate adenocarcinoma in some strains
[65]. It is well accepted that SV40 T antigen-induced transformation is mainly mediated via
inactivation of p53 and retinoblastoma (Rb) pathways [66], indicating that loss of these two
tumor suppressors may substantially contribute to the development of SCNC. Consistent
with the TRAMP model, a similar phenotype of prostate cancer with neuroendocrine
differentiation was also observed in the compound knockout mice with prostate-specific
deficiency in p53 and Rb, although either p53 deletion or Rb loss alone only resulted in
prostatic intraepithelial neoplasia (PIN) in aged mice [67]. These data suggest that
inactivation of both p53 and Rb pathways are required to cause the formation of SCNC in
the mice. Our studies have demonstrated that p53 mutation is likely a critical molecular
event for human SCNC but it remains to be determined if inactivation of Rb is also required.
In addition to genetically engineered mouse models, the tissue recombination/transplantation
model of prostate cancer is a very efficient approach to rapidly interrogate the functional
consequences of various genetic alterations central to the initiation and progression of the
human disease [68]. By appropriate reconstitution of the epithelial-stroma interactions to
mimic the native tumor microenvironment, the tissue recombination model consisting of
adult prostate epithelial cells and embryonic urogenital sinus mesenchymal cells can
faithfully recapitulate human prostate cancer evolution as well as the neoplastic lesions
developed in transgenic mice [69,70]. Furthermore, by incorporating other genetic tools
such as lentivirus-based gene transfer and shRNA-mediated knockdown, distinct
subpopulations of epithelial cells and mesenchymal cells can be genetically manipulated
with a high degree of flexibility. In a fast and cost-effective manner, this powerful system
can test both the cell-autonomous roles of genetic events in the epithelial compartment and
the influence of microenvironment on prostate carcinogenesis through paracrine actions
[71–73].
Importantly, primary prostate epithelial cells freshly isolated from benign human prostate
can be used as the starting material to study prostate cancer development in the tissue
recombination model, which makes it possible to examine many fundamental differences in
prostate cancer biology between mice and humans. Recently, we successfully established an
in vivo transformation assay using naïve human prostate epithelial cells directly harvested
from patients [74,75]. By coupling a lentiviral transduction technique with the in vivo
regeneration approach, we demonstrated that CD49fhiTrop2hi basal cells from primary
benign human prostate tissue are able to initiate prostate cancer in immunodeficient mice.
The synergistic effects of AKT activation, overexpression of ERG and AR in basal cells
closely recapitulated the histological and molecular features of human prostate cancer, with
loss of basal cells and expansion of malignant luminal cells expressing PSA and AMACR
[74]. These findings suggest that basal epithelial cells can be a cell of origin for human
prostate cancer. Although neuroendocrine differentiation is not observed in prostate tumors
derived from lentiviral transduced human basal cells in our current tissue recombination
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model, further investigation of the cellular origins of SCNC and identification of genetic and
epigenetic changes in neuroendocrine differentiation will facilitate the establishment of
relevant mouse models of SCNC, providing insights into the pathogenesis of SCNC and the
development of effective therapeutic strategies for this aggressive prostate malignancy.
6 Future direction
With continuous improvement in technologies and the significant reduction in cost for high-
throughput sequencing, remarkable advances have been made in molecular characterization
of prostate cancer. These findings at the molecular level are being translated into valuable
diagnostic biomarkers and prognostic predictors in the clinic, offering an opportunity for
patient stratification and personalized therapy. However, several unique features of prostate
cancer, including vastly different biology of different tumors, tumor multifocality, tumor
heterogeneity and the preference of bone as metastatic sites, pose significant challenges for
the acquisition and analyses of tumor samples. The exact roles of many newly identified
genetic alterations in prostate carcinogenesis remain uncertain. In addition, the contribution
of other factors, such as epigenetic changes, to ethnic variation and histological subtype
differences in prostate cancer has not been extensively investigated. Despite these
limitations and challenges, the recent molecular findings have provided strong candidates
for the development of novel targeted therapeutic agents. Combination therapies targeting
multiple molecules and pathways will likely substantially improve the clinical outcome of
patients with advanced prostate cancer in the near future.
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Figure 1.
The model of neuroendocrine differentation of prostate cancer and the development of small
cell neuroendocrine carcinoma after androgen deprivation therapy.
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Table 1
The prevalence of key genetic events for prostate carcinogenesis among different ethnic groups
Genetic alteration Prevalance in
Asian patients (%)
Frequency in patients
from Western
countries (%)
ERG-TMPRSS2 fusion 8–21 [19,21–23] 50–70 [17]
PTEN inactivation 34 [24] 70 [24,30]
CTAGE-KHDRBS3 fusion 37 [21] Unkown
USP9Y-TTTY15 fusion 35 [21] Unkown
KRAS mutations 7–17 [25–29] Up to 3 [25,31]
BRAF copy number gain 29 [28] 9 [28]
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